

# ASX Announcement

Medibio Limited – 20 June 2022



## UPDATE ON VOLUNTARY SUSPENSION

**Melbourne, Australia and Minneapolis, USA – 20 June 2022: Medibio Limited (MEB or the Company) (ASX: MEB) (OTCPINK: MDBIF)** would like to provide an update to the market following the letter announced on 16 June 2022 in relation to the voluntary suspension of the Company quoted securities (ASX: MEB and MEBOC) pending the announcement of a capital raising.

The Company now expects to make an announcement in relation to the capital raising before the commencement of trading on 21 June 2022 and confirms its request that the suspension will continue until the announcement is made.

– ENDS –

**For and on Behalf of the Board of Directors:**

Mathew Watkins - Company Secretary

T: +61 3 9692 7222

**About Medibio Limited**

Medibio (ASX: MEB) (OTCPINK: MDBIF) is a health technology company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions. Through their Corporate Health product, the Company offers mental well-being solutions for businesses and are also developing products to serve the healthcare provider market. The company was founded in Australia, with offices located in Melbourne (Vic) and U.S. offices in Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTC Pink Open Market. Investors can find additional information on [www.otcmarkets.com](http://www.otcmarkets.com) and [www.asx.com.au](http://www.asx.com.au).